XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.21.2

Net Loss Per Share | 9 Months Ended
--- | ---
Sep. 30, 2021
Earnings Per Share [Abstract] |
Net Loss Per Share | Note 11 — Net Loss Per Share The “Net loss per share basic and diluted” for the respective periods indicated - is as follows: Schedule of Basic and Fully Diluted Net Loss Per Share
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Numerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (6,956,619 | ) |  | $ | (2,021,677 | ) |  | $ | (16,772,393 | ) |  | $ | (5,548,873 | )
Denominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average common shares outstanding, basic and diluted |  |  | 14,114,707 |  |  |  | 14,114,707 |  |  |  | 14,114,707 |  |  |  | 14,114,347 |
Net Loss per share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net loss per share - basic and diluted |  | $ | (0.49 | ) |  | $ | (0.14 | ) |  | $ | (1.19 | ) |  | $ | (0.39 | )
Basic weighted-average number of shares of common stock outstanding for the three and nine months ended September 30, 2021 and 2020 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows: Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Earnings Per Share
|  | September 30, |
|  | 2021 |  |  | 2020 |
Lucid Diagnostics Inc. 2018 Equity Plan: |  |  |  |  |  |  |  |
- stock options |  |  | 975,942 |  |  |  | 975,942 |
- unvested restricted stock awards |  |  | 1,813,135 |  |  |  | — |
Stock options not granted under a plan |  |  | 423,300 |  |  |  | 423,300 |
Total |  |  | 3,212,377 |  |  |  | 1,399,242 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration